ColoPrint aids prediction of colorectal cancer relapse
 

A novel microarray-based 18-gene expression tool known as ColoPrint significantly improves prognostic accuracy in stage II colon cancer patients who have undergone surgery, suggest study findings.Licensed from Medwire news with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.



More...